Logo

Innovent Reports the Acceptance of its NDA by the NMPA for Mazdutide to Treat Overweight or Obese Adults

Share this
Innovent

Innovent Reports the Acceptance of its NDA by the NMPA for Mazdutide to Treat Overweight or Obese Adults

Shots:

  • The NDA was submitted based on the P-III (GLORY-1) trial evaluating the safety & efficacy of Mazdutide (4 or 6mg) vs PBO in Chinese overweight or obese adults
  • The results depicted superior effects of Mazdutide vs PBOs in body weight change from baseline to wk32 & proportion of participants with a weight loss of ≥5% at wk32 along with the proportion with a weight loss of ≥10% or ≥15%, changes in waist circumference, systolic BP, TG, LDL-C, total cholesterol, serum uric acid & ALT. The results are expected to be presented at upcoming medical conferences in 2024
  • Innovent signed an exclusive license agreement with Eli Lilly for the development & potential commercialization of Mazdutide (OXM3), a GLP-1R & GCGR dual agonist

Ref: Innovent | Image: Innovent

Related News:- Innovent Reports the Result Of Mazdutide (IBI362) in the P-II Study on Chinese Patients with Type-2 Diabetes (T2D)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions